Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Withdrawn 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 26Myelodysplastic Syndromes 13Recurrence 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Chronic 4Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Thrombocythemia, Essential 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Primary Myelofibrosis 1Polycythemia Vera 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myeloid Malignancies 1Myelodysplastic-Myeloproliferative Diseases 1Lymphodepleting Chemotherapy 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Hypomethylating Agent 1Human Papillomavirus-Negative Neck Squamous Cell Carcinoma 1Hodgkin Disease 1Hematologic Neoplasms 1Congenital Bone Marrow Failure Syndromes 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1Accelerated Phase Myeloproliferative Neoplasm 1

Interventions

Specimen Handling 7ruxolitinib 6Stem Cell Transplantation 5Cyclophosphamide 4Biopsy 4fludarabine 3Mycophenolic Acid 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3Whole-Body Irradiation 2Tacrolimus 2Sirolimus 2Methotrexate 2Melphalan 2Hematopoietic Stem Cell Transplantation 2Blood Component Removal 2thymoglobulin 1talazoparib 1tagraxofusp 1reparixin 1poly ICLC 1piperine 1pegylated granulocyte colony-stimulating factor 1merphos 1letermovir 1iadademstat 1fludarabine phosphate 1fedratinib 1demethoxycurcumin 1decitabine and cedazuridine drug combination 1daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Primary Myelofibrosis × Decitabine × Clear all
NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

University of Washington

Phase 2 Recruiting
25 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡